167 related articles for article (PubMed ID: 31714595)
1. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study.
Gosain R; Ball S; Rana N; Groman A; Gage-Bouchard E; Dasari A; Mukherjee S
Cancer; 2020 Feb; 126(4):792-799. PubMed ID: 31714595
[TBL] [Abstract][Full Text] [Related]
2. Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: A population-based analysis of 6271 cases.
Hallet J; Law CH; Karanicolas PJ; Saskin R; Liu N; Singh S
Cancer; 2015 Jul; 121(13):2214-21. PubMed ID: 25823667
[TBL] [Abstract][Full Text] [Related]
3. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
Hallet J; Law CH; Cukier M; Saskin R; Liu N; Singh S
Cancer; 2015 Feb; 121(4):589-97. PubMed ID: 25312765
[TBL] [Abstract][Full Text] [Related]
4. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
5. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
Allan B; Davis J; Perez E; Lew J; Sola J
Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065
[TBL] [Abstract][Full Text] [Related]
6. Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors.
Marincola Smith P; Baechle J; Tan MC; Solórzano CC; Lopez-Aguiar AG; Dillhoff M; Beal EW; Poultsides G; Cannon JGD; Rocha FG; Crown A; Cho CS; Beems M; Winslow ER; Rendell VR; Krasnick BA; Fields RC; Maithel SK; Bailey CE; Idrees K
Ann Surg Oncol; 2020 Sep; 27(9):3147-3153. PubMed ID: 32219725
[TBL] [Abstract][Full Text] [Related]
7. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
Perry AM; Brunner AM; Zou T; McGregor KL; Amrein PC; Hobbs GS; Ballen KK; Neuberg DS; Fathi AT
Cancer; 2017 Jul; 123(13):2561-2569. PubMed ID: 28464280
[TBL] [Abstract][Full Text] [Related]
8. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors.
Shen C; Gu D; Zhou S; Xu Y; Sarshekeh AM; Halperin D; Shih YT; Yao JC; Dasari A
Pancreas; 2019; 48(10):1373-1379. PubMed ID: 31688604
[TBL] [Abstract][Full Text] [Related]
9. Rural patients with oral squamous cell carcinoma experience better prognosis and long-term survival.
Harris JA; Hunter WP; Hanna GJ; Treister NS; Menon RS
Oral Oncol; 2020 Dec; 111():105037. PubMed ID: 33096312
[TBL] [Abstract][Full Text] [Related]
10. Differences in cancer presentation, treatment, and mortality between rural and urban patients diagnosed with kidney cancer in the United States.
Connors C; Levy M; Chin CP; Wang D; Omidele O; Larenas F; Palese M
Urol Oncol; 2024 Mar; 42(3):72.e9-72.e17. PubMed ID: 38195330
[TBL] [Abstract][Full Text] [Related]
11. Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study.
Lu L; Shang Y; Mullins CS; Zhang X; Linnebacher M
Future Oncol; 2021 Feb; 17(5):549-563. PubMed ID: 33401958
[No Abstract] [Full Text] [Related]
12. Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
Mulvey CK; Paciorek A; Moon F; Steiding P; Shih B; Gubens MA; Zhang L; Bergsland EK; Cheng I
Endocr Relat Cancer; 2024 Jan; 31(1):. PubMed ID: 37882324
[TBL] [Abstract][Full Text] [Related]
13. Effect of rural and urban geography on larynx cancer incidence and survival.
Zuniga SA; Lango MN
Laryngoscope; 2018 Aug; 128(8):1874-1880. PubMed ID: 29238975
[TBL] [Abstract][Full Text] [Related]
14. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?
Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE
Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986
[TBL] [Abstract][Full Text] [Related]
15. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
[TBL] [Abstract][Full Text] [Related]
16. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
[TBL] [Abstract][Full Text] [Related]
17. Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma.
Zhou K; Pickering TA; Gainey CS; Cockburn M; Stern MC; Liu L; Unger JB; El-Khoueiry AB; Terrault NA
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442663
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population-based study.
Tian FX; Cai YQ; Zhuang LP; Chen MF; Xiu ZB; Zhang Y; Liu H; Liu ZH; Liu GP; Zeng C; Lin FL; Liu J; Huang ST; Zhang LZ; Lin HY
Cancer Med; 2018 Nov; 7(11):5359-5369. PubMed ID: 30311450
[TBL] [Abstract][Full Text] [Related]
19. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival.
Yang Z; Wang W; Lu J; Pan G; Pan Z; Chen Q; Liu W; Zhao Y
Cell Physiol Biochem; 2018; 45(1):389-396. PubMed ID: 29402806
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States.
Shah S; Gosain R; Groman A; Gosain R; Dasari A; Halfdanarson TR; Mukherjee S
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33916960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
